Skip to main content
. 2016 May 23;10:643. doi: 10.3332/ecancer.2016.643

Table 2. Baseline and postbiopsy International Index Erectile Function-5 Score.

N at pre-TPSBx N at one month post-TPSBx N at three months post-TPSBx N at six months post-TPSBx
First TP
Without ED (IIEF-5 22–25) 29 (45.3%) 0 20 (31.3%) 29 (45.3%)
Mild ED (IIEF-5 17–21) 23 (35.9%) 12 (18.8%) 29 (45.3%) 23 (35.9%)
Mild/Moderate ED (IIEF-5 12–16) 3 (4.7%) 9 (14.1%) 5 (7.8%) 4 (6.3%)
Moderate ED (IIEF-5 8–11) 5 (7.8%) 23 (35.9%) 7 (10.9%) 6 (9.4%)
Severe ED (IIEF-5 1–7) 2 (3.1%) 18 (28.1%) 0 0
No sexual function (IIEF-5 0) 2 (3.1%) 2 (3.1%) 2 (3.1%) 2 (3.1%)
Missing 0 0 1 (1.6%) 0
Second TP
Without ED (IIEF-5 22–25) 13 (20.3%) 3 (4.7%) 5 (7.8%) 12 (18.7%)
Mild ED (IIEF-5 17–21) 27 (42.2%) 5 (7.8%) 25 (39.1%) 24 (37.5%)
Mild/Moderate ED (IIEF-5 12–16) 11 (17.2%) 9 (14.1%) 12 (18.8%) 11 (17.2%)
Moderate ED (IIEF-5 8–11) 5 (7.8%) 7 (10.9%) 4 (6.2%) 8 (12.5%)
Severe ED (IIEF-5 1–7) 3 (4.7%) 25 (39.1%) 4 (6.2%) 1 (1.6%)
No sexual function (IIEF-5 0) 5 (7.8%) 15 (23.4%) 9 (14.1%) 8 (12.5%)
Missing 0 0 5 (7.8%) 0